Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluska

Showing results (341-350 of 366) with videos related to

Pageof 37
Sort By:
Kidney & Blood Pressure Research|December 4, 2017
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled TrialMatthew A Roberts, Darsy Darssan, Sunil V Badve, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Tumorgrafts as in vivo surrogates for women with ovarian cancerS John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell, Judith Abrams, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
Cancer Research|January 28, 2010
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis, Lynn C Hartmann, William A Cliby, et al.
Pageof 37

Showing results (341-350 of 366) with videos related to

Sort By:
Pageof 37
Kidney & Blood Pressure Research|December 4, 2017
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled TrialMatthew A Roberts, Darsy Darssan, Sunil V Badve, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Tumorgrafts as in vivo surrogates for women with ovarian cancerS John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell, Judith Abrams, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
Cancer Research|January 28, 2010
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis, Lynn C Hartmann, William A Cliby, et al.
Pageof 37